SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 102.96 |
| Enterprise Value ($M) | 51.67 |
| Book Value ($M) | 195.14 |
| Book Value / Share | 2.75 |
| Price / Book | 0.53 |
| NCAV ($M) | 108.15 |
| NCAV / Share | 1.52 |
| Price / NCAV | 0.95 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.40 |
| Return on Assets (ROA) | -0.26 |
| Return on Equity (ROE) | -0.40 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.70 |
| Current Ratio | 5.70 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 232.53 |
| Assets | 319.52 |
| Liabilities | 124.38 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 35.58 |
| Operating Income | -117.18 |
| Net Income | -105.32 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -65.16 |
| Cash from Investing | -51.27 |
| Cash from Financing | 45.34 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Wasatch Advisors Inc | 10.50 | ||
| 13G | Morgan Stanley | 5.40 | ||
| 13G/A | Lynx1 Capital Management LP | 9.90 | 119.52 | |
| 13G/A | Soleus Capital Master Fund, L.P. | 9.40 | 158.37 | |
| 13G | Orbimed Advisors Llc | 4.20 | ||
| 13G/A | Commodore Capital Lp | 4.80 | -10.25 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 0.60 | -84.68 | |
| 13G/A | Point72 Asset Management, L.P. | 1.90 | -50.92 | |
| 13G | BlackRock, Inc. | 7.10 | 0.00 | |
| 13G/A | State Street Corp | 4.35 | -58.13 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 340,450 | 1,074,371 | 31.69 | |
| 246,425 | 988,099 | 24.94 | |
| 453,271 | 2,254,337 | 20.11 | |
| 274,456 | 965,856 | 28.42 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BMRN – BioMarin Pharmaceutical Inc. | BPMC – Blueprint Medicines Corporation |
| CABA – Cabaletta Bio, Inc. | CGC – Canopy Growth Corporation |
| CGEM – Cullinan Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io